All In Biotech

Drug Trial Radar · NCT04115293

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

174

Actual

Start

Sep 17, 2019

Primary completion

Dec 30, 2021

Study completion Dec 30, 2021

Sponsor

Lead sponsor
Ra Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

Conditions

  • Myasthenia Gravis, Generalized

Interventions

  • zilucoplan (RA101495)Drug

    Daily subcutaneous (SC) injection

  • PlaceboDrug

    Daily subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total ScoreTime frame: From Baseline to End of Treatment (Week 12)

Locations

77 sites in 10 countries. Site status is shown where the registry gives one.

  • Site 41: Diagnostic and Medical Clinic

    Mobile, Alabama

  • Site 116: Neuromuscular Clinic and Research Center

    Phoenix, Arizona

  • Site 4: University of Southern California

    Los Angeles, California

  • Site 31: University of California Irvine

    Orange, California

  • Site 220: Investigator Site

    Pasadena, California

  • Site 160: Forbes Norris MDA/ALS Research and Treatment Center

    San Francisco, California

  • Site 24: Yale University

    New Haven, Connecticut

  • Site 27: George Washington University

    Washington D.C., District of Columbia

  • Site 182: Gelasio Baras Neurology

    Miami, Florida

  • Site 25: University of South Florida

    Tampa, Florida

  • Site 135: Augusta University Medical Center

    Augusta, Georgia

  • Site 176: Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Site 188: North Shore Medical Group - Glenview

    Glenview, Illinois

  • Site 156: Indiana University Health Neuroscience Center

    Indianapolis, Indiana

  • Site 32: Kansas University Medical Center Research Institute

    Kansas City, Kansas

  • Site 221: Neurology Center of New England

    Foxborough, Massachusetts

  • Site 33: Detroit medical Center - University Health Center

    Detroit, Michigan

  • Site 49: Michigan State University

    East Lansing, Michigan

  • Site 127: University of Minnesota

    Minneapolis, Minnesota

  • Site 134: Neurology and Sleep Disorders Clinic

    Columbia, Missouri

  • Site 117: Las Vegas Clinic

    Las Vegas, Nevada

  • Site 123: Northwell Health Neuroscience Institute

    Great Neck, New York

  • Site 23: Hospital for Special Surgery

    New York, New York

  • Site 47: Mount Sinai Hospital

    New York, New York

  • Site 22: University of North Carolina

    Chapel Hill, North Carolina

  • Site 15: Duke University

    Durham, North Carolina

  • Site 122: Cleveland Clinic

    Cleveland, Ohio

  • Site 38: Ohio State University

    Columbus, Ohio

  • Site 40: Allegheny Neurological Associates

    Pittsburgh, Pennsylvania

  • Site 128: Medical University of South Carolina

    Charleston, South Carolina

  • Site 185: Neurology Clinic Cordova

    Cordova, Tennessee

  • Site 131: Austin Neuromuscular Center

    Austin, Texas

  • Site 19: University of Texas Southwestern

    Dallas, Texas

  • Site 39: University of Utah

    Salt Lake City, Utah

  • Site 164: University of Virginia Health System

    Charlottesville, Virginia

  • Site 154: University of Washington

    Seattle, Washington

  • Site 45: Center for Neurological Disorders

    Milwaukee, Wisconsin

  • Site 44: London Health Sciences Centre University Hospital

    London, Ontario, Canada

  • Site 11: Montreal Neurological Institute and Hospital (McGill University)

    Montreal, Quebec, Canada

  • Site 191: Centre Hosptitalier Universitaire d'Angers

    Angers, France

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.